书名：Bad Blood坏血:一个硅谷巨头的秘密与谎言

作者：John Carreyrou
出版社名称：Vintage
出版时间：2020
语种：英语
ISBN：9780593081648
商品尺寸：10.5 x 3.4 x 17.5 cm
包装：平装
页数：448（以实物为准）

★两度获得普利策新闻奖的作者约翰·卡雷鲁

★引爆欧美阅读热潮的畅销书，比尔·盖茨力荐

★《纽约时报》、《时代周刊》、《华尔街日报》、《华盛顿邮报》年度图书

★改编为同名电影，由奥斯卡影后詹尼佛·劳伦斯主演

Bad Blood《坏血》是The Wall Street Journal《华尔街日报》记者约翰·卡雷鲁（John Carreyrou）的新闻纪实作品，在本书中，作者揭露了继“安然事件”之后规模极为庞大的企业诈欺案件，讲述了一个关于野心与被利益蒙蔽双眼的故事。

Reviews
“Chilling. . . . Reads like a thriller. . . . Carreyrou tells [the Theranos story] virtually to perfection.” —The New York Times 

“Engrossing. . . . Hard to put down. . . . Boasts movie-scene detail. . . . Theranos employees are the story’s heroes, with the force of journalism not far behind.” —Science

“A veritable page-turning. . . . Gripping. . . . Presents comprehensive evidence of the fraud perpetrated by Theranos chief executive Elizabeth Holmes... Unveils many dark secrets of Theranos that have not previously been laid bare.” —Nature

“This is a ‘stay up all night to read’ book that is just as propulsive, shocking, and riveting as the best thriller novels.” —Bustle

“Riveting. . . . Compelling. . . . [Carreyrou’s] unmasking of Theranos is a tale of David and Goliath.” —Financial Times

2014年，伊丽莎白·霍姆斯所创立的企业希拉洛斯由于其革命性的血液检测技术——在一滴血上进行两百多项专业检测——在短短十年间成长为硅谷商业价值的独角兽公司。霍姆斯本人更是跻身全美四百大富豪榜，入选《时代》杂志影响全球的百大人物，一跃成为硅谷亿万女性创业家。希拉洛斯的身后隐藏着豪华阵容的董事会成员——美国前国务卿乔治·舒尔茨、亨利·基辛格，媒体大亨鲁伯特·默多克，甲骨文创始人拉里·埃里森，传奇创投家唐纳德·卢卡斯等。就在人们期待着希拉洛斯成长为下一个苹果或者谷歌时，一个真相逐渐显现——希拉洛斯所声称的革命技术是假的，这个商业神话内核的只有一个，那就是谎言。

一场价值近百亿美元的骗局如何被精心打造？一个毫无医学背景的斯坦福辍学生缘何能蒙骗住一众美国政商界大佬？两届普利策新闻奖得主约翰·卡雷鲁不畏威胁、追踪，以冷静的笔触和完整的细节，揭露了这个自安然公司之后规模巨大的企业诈骗案内幕。

In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees.

约翰·卡雷鲁，《华尔街日报》调查记者，曾两度获得普立策新闻奖。他对希拉洛斯的深入报导，获得了乔治．波克奖财经报导奖项、罗布杰出商业财经新闻奖的专题报导奖项，以及巴莱特&史提尔调查新闻银奖。《滴血成金》是他的第一本著作，发表后获得包括金融时报与麦肯锡年度商业书籍在内的多项大奖，并售出近20国的翻译版权。卡雷鲁目前与妻子、三名子女住在纽约布鲁克林。

  
John Carreyrou, a two-time Pulitzer Prize winner, was a reporter at The Wall Street Journalfor twenty years. For his extensive coverage of Theranos, Carreyrou was awarded the George Polk Award for Financial Reporting, the Gerald Loeb Award for Distinguished Business and Financial Journalism in the category of beat reporting, and the Barlett & Steele Silver Award for Investigative Business Journalism. Bad Bloodwas named the Financial Times and McKinsey Business Book of the Year. Carreyrou lives in Brooklyn, New York, with his wife and three children.

November 17, 2006
Tim Kemp had good news for his team.

The former IBM executive was in charge of bioinformatics at Theranos, a startup with a cutting-edge blood-testing system. The company had just completed its first big live demonstration for a pharmaceutical company. Elizabeth Holmes, Theranos’s twenty-two-year-old founder, had flown to Switzerland and shown off the system’s capabilities to executives at Novartis, the European drug giant.

“Elizabeth called me this morning,” Kemp wrote in an email to his fifteen-person team. “She expressed her thanks and said that, ‘it was perfect!’ She specifically asked me to thank you and let you all know her appreciation. She additionally mentioned that Novartis was so impressed that they have asked for a proposal and have expressed interest in a financial arrangement for a project. We did what we came to do!”

This was a pivotal moment for Theranos. The three-year-old startup had progressed from an ambitious idea Holmes had dreamed up in her Stanford dorm room to an actual product a huge multinational corporation was interested in using.

Word of the demo’s success made its way upstairs to the second floor, where senior executives’ offices were located.

One of those executives was Henry Mosley, Theranos’s chief financial officer. Mosley had joined Theranos eight months earlier, in March 2006. A rumpled dresser with piercing green eyes and a laid-back personality, he was a veteran of Silicon Valley’s technology scene. After growing up in the Washington, D.C. area and getting his MBA at the University of Utah, he’d come out to California in the late 1970s and never left. His first job was at chipmaker Intel, one of the Valley’s pioneers. He’d later gone on to run the finance departments of four different tech companies, taking two of them public. Theranos was far from his first rodeo.

What had drawn Mosley to Theranos was the talent and experience gathered around Elizabeth. She might be young, but she was surrounded by an all-star cast. The chairman of her board was Donald L. Lucas, the venture capitalist who had groomed billionaire software entrepreneur Larry Ellison and helped him take Oracle Corporation public in the mid-1980s. Lucas and Ellison had both put some of their own money into Theranos.